Fucoidan for COVID-19
Fucoidan has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Inhibitory activities of marine sulfated polysaccharides against SARS-CoV-2, Food & Function, doi:10.1039/D0FO02017F ,
<p>Sulfated polysaccharide from sea cucumber (SCSP), fucoidan from brown algae, and iota-carrageenan from red algae show inhibitory activities against SARS-CoV-2.</p>
Antiviral activity of sulfated polysaccharides from marine algae and its application in combating COVID-19: Mini review, Bioresource Technology Reports, doi:10.1016/j.biteb.2020.100623 ,
Fucoidan and Lung Function: Value in Viral Infection, Marine Drugs, doi:10.3390/md19010004 ,
Compromised lung function is a feature of both infection driven and non-infective pathologies. Viral infections—including the current pandemic strain SARS-CoV-2—that affect lung function can cause both acute and long-term chronic damage. SARS-CoV-2 infection suppresses innate immunity and promotes an inflammatory response. Targeting these aspects of SARS-CoV-2 is important as the pandemic affects greater proportions of the population. In clinical and animal studies, fucoidans have been shown to increase innate immunity and decrease inflammation. In addition, dietary fucoidan has been shown to attenuate pulmonary damage in a model of acute viral infection. Direct inhibition of SARS-CoV-2 in vitro has been described, but is not universal. This short review summarizes the current research on fucoidan with regard to viral lung infections and lung damage.
Low molecular weight fucoidan attenuating pulmonary fibrosis by relieving inflammatory reaction and progression of epithelial-mesenchymal transition, Carbohydrate Polymers, doi:10.1016/j.carbpol.2021.118567 ,
A state-of-the-art review on fucoidan as an antiviral agent to combat viral infections, Carbohydrate Polymers, doi:10.1016/j.carbpol.2022.119551 ,
Therapeutic Applications of Fucoidans and their Potential to Act against COVID-19, Current Pharmaceutical Design, doi:10.2174/1381612829666221207093215 ,
Abstract: In this review article, we present the updated evidence of therapeutic applications of fucoidan (a seaweed polysaccharide) and its novel potential to treat infectious diseases such as coronavirus disease (COVID-19). Because of their many biological activities, seaweeds have been identified as a rich and useful source of bioactive chemicals. Sulfated polysaccharides from the sea are considered a source of physiologically active chemicals that might be used in medication development. Antitumor, antiviral, antioxidant, antibacterial, anticoagulant, and immune-inflammatory properties have all been described for these compounds. By interfering at various phases of viral infection, marine sulfated polysaccharide has a virucidal effect. As a result, it opens the door to the development of antiviral treatments. Virus entry into host cells is an initial process, avoiding this type of entry makes any precautionary measure effective. The inhibitory action of certain marine sulfated polysaccharides against coronavirus was tested, and fucoidan, iota-carrageenan, and sea cucumber sulfated polysaccharides all showed a substantial antiviral impact. Fucoidan is one of the useful sulfated polysaccharides that has been widely studied and explored in various research. There are different sources of fucoidans, which have been used in the treatment of viral infection. Additionally, we highlight the mechanism of action of fuocidan against COVID-19. Hence, we could suggest that COVID-19 might be prevented and treated using these sulfated polysaccharides. This review thus highlights ample evidence to support the hypothesis that a large number of drugs have been developed from powerful compounds isolated from marine seaweeds.
A Comprehensive Review on Potentially Therapeutic Agents against COVID-19 from Natural Sources, Current Traditional Medicine, doi:10.2174/2215083809666230203142343 ,
Abstract: Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the recent pandemic and worldwide outbreak of respiratory disease. Since there are no known specific drugs for fighting this virus and the process for new drug development is lengthy, scientists have been trying to develop drugs against this viral infection. The potent antiviral activity of natural products has been confirmed in several previous studies. Viral and host proteins contributing to COVID-19 infections can be targeted by natural compounds derived from plants, marine organisms, and microorganisms. The most important of these compounds are polyphenols (e.g., anthraquinone polyphenol, hinokinin, curcumin, and epigallocatechin gallate), alkaloids (e.g., isoquinoline, 10- hydroxyusambarensine, anisotine, and adhatodine), and terpenoids (salvinorin A, thymoquinone, bilobalide, ginkgolide A, and celastrol) from plants, sulphated polysaccharides (carrageenans, chondroitin sulfate C, and fucoidan) from marine organisms, and glycocin F and lactococcin G phycocyanin, and lipopeptide from microorganisms. This study reviews these compounds and their mechanism of action for treating COVID-19 infection and guides researchers in developing effective and safe therapeutic agents against this disease from naturally derived compounds.
Screening of Antiviral Efficacy of Few Seaweeds of Tamil Nadu Coast, Proceedings of Anticancer Research, doi:10.26689/par.v7i5.5161 ,
Lately there has been a lot of interest worldwide in studies on the antiviral activities of marine natural secondary metabolites, notably marine polysaccharides. It has been established that polysaccharides made from marine sources and their derivatives have antiviral effects against potent viruses. Agricultural, biological, food, and pharmaceutical industries all make extensive use of goods obtained from algae. The most well-known chemical components found in algae are polysaccharides, which have been the subject of a variety of studies because of their varied bioactivities. Polysaccharides made from algae have recently risen to the top of pharmaceutical research due to their fascinating antiviral potential. Currently, COVID-19 can be prevented with vaccination, but the brown alga Sargassum wightii has several bioactive compounds that have the following qualities and may be a better option. S. wightii is one of the marine algae species that is rich in sulfated polysaccharides, the secondary metabolites which have antiviral action and the capacity to prevent viral proliferation. Fucoidan, a long-chain sulfated polysaccharide found in various brown algae, has potent antiviral effects. Additionally, sulfated polysaccharides from green algae (such as ulvans) and red algae (such as carrageenan), and lectins from red algae (such as griffithsin) have antiviral therapeutic agents against coronaviruses and other viruses. This research focuses on screening seaweeds for possible antiviral compounds to treat viral infections notably COVID-19.
Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478 ,
Utilization of Marine Seaweeds as a Promising Defense Against COVID-19: a Mini-review, Marine Biotechnology, doi:10.1007/s10126-023-10214-7 ,
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.